Catheter Precision (NYSEAMERICAN:VTAK) Releases Quarterly Earnings Results

Catheter Precision (NYSEAMERICAN:VTAK) announced its quarterly earnings results on Monday. The company reported ($1.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($20.90) by $19.51, FiscalAI reports. The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $1.60 million. Catheter Precision had a negative return on equity of 114.26% and a negative net margin of 2,044.08%.

Catheter Precision Stock Performance

Shares of VTAK traded up $0.07 during trading hours on Monday, reaching $0.83. 446,920 shares of the company traded hands, compared to its average volume of 779,751. The stock has a market capitalization of $2.23 million, a P/E ratio of -0.04 and a beta of -1.04. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.46. Catheter Precision has a 12-month low of $0.76 and a 12-month high of $15.68. The business has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.68.

Institutional Investors Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent SEC filing. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.